<DOC>
	<DOCNO>NCT02806375</DOCNO>
	<brief_summary>A number group demonstrate low incidence acute chronic graft-versus-host disease ( GVHD ) post-transplantation cyclophosphamide ( PTCy ) haploidentical unrelated allogeneic stem cell transplantation ( SCT ) . Still relapse underlining malignancy problem prophylaxis . Ruxolitinib currently one promise drug treatment steroid-refractory GVHD . On hand , primary indication myelofibrosis , demonstrate ruxolitinib allogeneic SCT might improve outcome . This pilot trial evaluate whether combination PTCy ruxolitinib facilitates adequate GVHD control , decrease risk graft failure disease progression myelofibrosis patient .</brief_summary>
	<brief_title>PTCy Ruxolitinib GVHD Prophylaxis Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antineoplastic Agents , Alkylating</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must indication allogeneic hematopoietic stem cell transplantation Diagnosis : Primary myelofibrosis Secondary myelofibrosis Signed informed consent Matched relate , 810/10 HLAmatched unrelated haploidentical donor available . The HLA typing perform following genetic locus : HLAA , HLAB , HLACw , HLADRB1 , HLADQB1 . No second tumor No severe concurrent illness Moderate severe cardiac dysfunction , leave ventricular ejection fraction &lt; 50 % Moderate severe decrease pulmonary function , FEV1 &lt; 70 % DLCO &lt; 70 % predict Respiratory distress &gt; grade I Severe organ dysfunction : AST ALT &gt; 5 upper normal limit , bilirubin &gt; 1.5 upper normal limit , creatinine &gt; 2 upper normal limit Creatinine clearance &lt; 60 mL/min Uncontrolled bacterial fungal infection time enrollment Requirement vasopressor support time enrollment Karnofsky index &lt; 30 % Pregnancy Somatic psychiatric disorder make patient unable sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Antineoplastic Agents , Alkylating</keyword>
	<keyword>Myeloablative Agonists</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Allogeneic</keyword>
</DOC>